1 Min Read
April 19 (Reuters) - Catalyst Pharmaceuticals Inc:
* CATALYST PHARMACEUTICALS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 3 TRIAL OF FIRDAPSE® IN MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.